Skip to content

R-Pharm Germany Files for Insolvency Amid Sanctions and Geopolitical Strife

A historic German pharma plant with roots dating back to 1860 now fights for survival. Can new investors save 300 jobs and revive its legacy?

The image shows an old German 100 Reichsmark banknote from 1933, with the text "Metallgesellschaft...
The image shows an old German 100 Reichsmark banknote from 1933, with the text "Metallgesellschaft Aktie" printed on it.

R-Pharm Germany Files for Insolvency Amid Sanctions and Geopolitical Strife

R-Pharm Germany, a subsidiary of the Russian pharmaceutical firm R-Pharm, has filed for insolvency. The company, based in Illertissen, employs around 300 people and still operates on a limited basis despite financial troubles. Its collapse follows years of disruption caused by geopolitical tensions and economic sanctions. The company's roots trace back to 1860, when Heinrich Mack founded it as a soap and drugstore goods producer. Pfizer later acquired the Illertissen plant in 1970 before R-Pharm took control in 2014. During the COVID-19 pandemic, the site was set to manufacture Russia's Sputnik V vaccine, but those plans never materialised.

The insolvency stems from EU sanctions and Moscow's retaliatory measures after Russia's invasion of Ukraine. These restrictions severed reliable cash flow between the Moscow-based parent company and its German subsidiary. Despite the difficult situation, the business continues to supply pharmaceuticals and dietary supplements to around 150 customers globally. Markus Fröhlich, the preliminary insolvency administrator, remains cautiously optimistic. He believes the conditions for restructuring are solid, even though the starting position is challenging. His team is now searching for an investor willing to take over the company and secure its future.

The insolvency process will determine whether R-Pharm Germany can survive under new ownership. For now, the company maintains limited operations while administrators work to stabilise its finances. The outcome will affect 300 employees and the wider pharmaceutical supply chain.

Read also:

Latest